Methods and compositions for treating celiac disease

Abstract

The invention features the treatment of gastrointestinal disorders associated with an innate immune response tiggered by alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM16, CMb, CMX1 / CMX3, CMX2, and / or alpha amylase inhibitor 0.53 (0.53). To this end, the invention features pharmaceutical compositions including neutralizing antibodies to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1 / CMX3, CMX2, and / or 0.53, food products containing reduced levels of CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1 / CMX3, CMX2, and / or 0.53 protein, the use of oral TLR4 inhibitors to block the effect of said alpha-amylase inhibitors, assays for identifying CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1 / CMX3, CMX2, and / or 0.53 content in food products, and assays for diagnosing subjects with a disorder related to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1 / CMX3, CMX2, and / or 0.53 triggered innate immune responses.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims benefit of U.S. Provisional Application Nos. 61 / 330,043, filed Apr. 30, 2010 and 61 / 417,613 filed Nov. 29, 2010, each of which is hereby incorporated by reference.STATEMENT AS TO FEDERALLY FUNDED RESEARCH[0002]This work was supported by grant number NIH 1R21AI078385A1-01 from the United States National Institutes of Health. The Government has certain rights in the invention.BACKGROUND OF THE INVENTION[0003]This invention relates to the treatment of celiac disease with compounds that decrease inflammation resulting from contact with wheat alpha Amylase inhibitors, including CM3 or 0.19.[0004]Celiac disease (CD) is an inflammatory small intestinal disorder, often accompanied by a malabsorptive syndrome which is caused in part by an uncontrolled immune reaction to ingested gluten proteins. The prevalence of this disease in affected populations such as the US, the Middle East, or Europe is 0.5-2.5%. Untreated, CD patie...

AI Technical Summary

Benefits of technology

The patent is about a new invention that involves a way to create plant products with reduced levels of a specific protein called AAI. This invention may help prevent negative gastrointestinal reactions in people with certain conditions like celiac disease, ulcerative colitis, and Crohn's disease. The patent includes a form of RNAi technology that can be used to reduce the levels of AAI in plants. Overall, this invention could help create safer and more tolerable food products for some people.

Problems solved by technology

However, a gluten free diet is difficult to maintain and non-dietary treatment alternatives are urgently needed.

Moreover, even a gluten free diet may not lead to remission in patients with refractory celiac disease.

Images